Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E.
Diabetologia. 2024 Mar 21. PMID: 38509341
Secondary Faculty
Elisabetta Patorno
Other Positions
Associate Professor of Medicine
Medicine-Brigham and Women's Hospital
Harvard Medical School
Links
Bibliography
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E.
Cardiovasc Diabetol. 2024 Mar 18. 23(1):103. PMID: 38500096
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events.
Suissa K, Cromer SJ, Patorno E.
JAMA. 2024 03 12. 331(10):884-885. PMID: 38470390
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E.
JAMA Intern Med. 2024 Mar 01. 184(3):265-274. PMID: 38285598
Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA Sentinel Innovation Center.
Desai RJ, Wang SV, Sreedhara SK, Zabotka L, Khosrow-Khavar F, Nelson JC, Shi X, Toh S, Wyss R, Patorno E, Dutcher S, Li J, Lee H, Ball R, Dal Pan G, Segal JB, Suissa S, Rothman KJ, Greenland S, Hernán MA, Heagerty PJ, Schneeweiss S.
BMJ. 2024 02 12. 384:e076460. PMID: 38346815
Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E.
Cardiovasc Diabetol. 2024 02 08. 23(1):57. PMID: 38331813
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.
Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, Gissler M, Huybrechts KF, Kjerpeseth LJ, Leinonen MK, Pazzagli L, Zoega H, Seely EW, Patorno E, Hernández-Díaz S.
JAMA Intern Med. 2024 Feb 01. 184(2):144-152. PMID: 38079178
A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
Fu EL, Mastrorilli J, Bykov K, Wexler DJ, Cervone A, Lin KJ, Patorno E, Paik JM.
Kidney Int. 2024 Mar. 105(3):618-628. PMID: 38101515
Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
Htoo PT, Paik JM, Alt E, Kim DH, Wexler DJ, Kim SC, Patorno E.
J Gerontol A Biol Sci Med Sci. 2023 12 01. 78(12):2426-2434. PMID: 36866496
Successful implementation of a stakeholder engagement program for pharmacoepidemiologic research.
Cromer SJ, Steiner B, York C, Mastrorilli J, Lake GA, Leibowitz S, Simmons L, Steppel-Reznik J, Low G, Fischer MA, Patorno E, Wexler DJ.
Pharmacoepidemiol Drug Saf. 2024 Jan. 33(1):e5727. PMID: 37985010